A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs Cediranib (Primary) ; Temsirolimus (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 04 May 2017 Planned End Date changed from 1 Sep 2013 to 1 Apr 2018.
- 26 Aug 2013 Planned End Date changed from 1 Feb 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 08 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.